ResoundingHealth
Search
  
Basic Drug Info
Drug Name:Temodar
Manufacturer:Schering Corporation
Other Info:

Copyright ©2004, Schering Corporation,Kenilworth, NJ 07033.

All rights reserved.Rev.

5/06



Clinical Trials:


Indications and Usage
TEMODAR (temozolomide) Capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.TEMODAR Capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma, ie, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
Glioblastoma Multiforme -- malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage and necrosis; may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways.

Anaplastic astrocytoma -- A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)

Disease Progression -- The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Contraindications

TEMODAR (temozolomide) Capsules are contraindicated in patients who have a history of hypersensitivity reaction to any of its components.

TEMODAR is also contraindicated in patients who have a history of hypersensitivity to DTIC, since both drugs are metabolized to MTIC.
Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

Warnings

Patients treated with TEMODAR Capsules may experience myelosuppression.

Prior to dosing, patients must have an absolute neutrophil count (ANC) ?1.5 × 109/L and a platelet count ?100 × 109/L.

A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 109/L and platelet count exceeds 100 × 109/L.

Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.

Very rare cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed.For treatment of newly diagnosed glioblastoma multiforme: Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42 day regimen.There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen.

However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.

This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.